A Phase 3, Prospective, Double-Blinded, Randomized Controlled Trial of the Micronized dHACM Injection As Compared To Saline Placebo Injection In The Treatment Of Plantar Fasciitis
Latest Information Update: 23 May 2022
Price :
$35 *
At a glance
- Drugs DHACM (Primary)
- Indications Plantar fasciitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors MiMedx
- 18 May 2022 Status changed from active, no longer recruiting to completed.
- 13 Sep 2021 According to a MiMedx media release, the company plans to review the full study results from this trial with investors at a future R&D Day, planned for later this year.
- 13 Sep 2021 Primary endpoint of change in VAS score has not been met, according to a MiMedx media release.